Peters M - Search Results

1

Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes.

van Den Brink EN, Turenhout EA, Davies J, Bovenschen N, Fijnvandraat K, Ouwehand WH, Peters M, Voorberg J. van Den Brink EN, et al. Among authors: peters m. Blood. 2000 Jan 15;95(2):558-63. Blood. 2000. PMID: 10627462 Free article.

2

Estrogens reduce plasma histidine-rich glycoprotein (HRG) levels in a dose-dependent way.

Hennis BC, Boomsma DI, Fijnvandraat K, Gevers Leuven JA, Peters M, Kluft C. Hennis BC, et al. Among authors: peters m. Thromb Haemost. 1995 Mar;73(3):484-7. Thromb Haemost. 1995. PMID: 7667832 Clinical Trial.

3

Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality.

Fijnvandraat K, Derkx B, Peters M, Bijlmer R, Sturk A, Prins MH, van Deventer SJ, ten Cate JW. Fijnvandraat K, et al. Among authors: peters m. Thromb Haemost. 1995 Jan;73(1):15-20. Thromb Haemost. 1995. PMID: 7740486

4

Endotoxin induced coagulation activation and protein C reduction in meningococcal septic shock.

Fijnvandraat K, Peters M, Derkx B, van Deventer S, ten Cate JW. Fijnvandraat K, et al. Among authors: peters m. Prog Clin Biol Res. 1994;388:247-54. Prog Clin Biol Res. 1994. PMID: 7831362 Review. No abstract available.

5

Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels.

Fijnvandraat K, Peters M, ten Cate JW. Fijnvandraat K, et al. Among authors: peters m. Br J Haematol. 1995 Oct;91(2):474-6. doi: 10.1111/j.1365-2141.1995.tb05325.x. Br J Haematol. 1995. PMID: 8547097 Clinical Trial.

6

Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock.

Wuillemin WA, Fijnvandraat K, Derkx BH, Peters M, Vreede W, ten Cate H, Hack CE. Wuillemin WA, et al. Among authors: peters m. Thromb Haemost. 1995 Dec;74(6):1436-41. Thromb Haemost. 1995. PMID: 8772216

7

Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients.

Fijnvandraat K, Berntorp E, ten Cate JW, Johnsson H, Peters M, Savidge G, Tengborn L, Spira J, Stahl C. Fijnvandraat K, et al. Among authors: peters m. Thromb Haemost. 1997 Feb;77(2):298-302. Thromb Haemost. 1997. PMID: 9157585 Clinical Trial.

8

The missense mutation Arg593 --> Cys is related to antibody formation in a patient with mild hemophilia A.

Fijnvandraat K, Turenhout EA, van den Brink EN, ten Cate JW, van Mourik JA, Peters M, Voorberg J. Fijnvandraat K, et al. Among authors: peters m. Blood. 1997 Jun 15;89(12):4371-7. Blood. 1997. PMID: 9192760 Free article.

9

A human alloantibody interferes with binding of factor IXa to the factor VIII light chain.

Fijnvandraat K, Celie PH, Turenhout EA, ten Cate JW, van Mourik JA, Mertens K, Peters M, Voorberg J. Fijnvandraat K, et al. Among authors: peters m. Blood. 1998 Apr 1;91(7):2347-52. Blood. 1998. PMID: 9516133 Free article.

10

Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593-->Cys substitution.

van den Brink EN, Timmermans SM, Turenhout EA, Bank CM, Fijnvandraat K, Voorberg J, Peters M. van den Brink EN, et al. Among authors: peters m. Thromb Haemost. 1999 May;81(5):723-6. Thromb Haemost. 1999. PMID: 10365744

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,181 results

Search Page

Filters